FCF YoY
-15.47%
OCF YoY
-14.33%
Capex YoY
-9.68%
FCF Conversion Δ
-1.1 pp
Free cash flow bridge for Pfizer (PFE) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: −$1.74B
FCF bridge breakdown for Pfizer (PFE) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | $11.22B | — |
| Operating Cash Flow | −$2.00B | -115.4% |
| Capital Expenditure | $268.00M | +15.4% |
| Free Cash Flow | $9.48B | — |
- Prior Free Cash Flow$11.22B
- Operating Cash Flow−$2.00B
- Capital Expenditure$268.00M
- Free Cash Flow$9.48B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement